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Circulating urokinase receptor 
as a cause of focal segmental 
glomerulosclerosis
Wei et al., Nat Med 2011; 17: 952–960; doi:10.1038/nm.2411
Focal segmental glomerulosclerosis (FSGS) is a major cause of 
end-stage renal disease. Effacement of podocyte foot processes 
marks the first ultrastructural step associated with the loss of 
plasma proteins into the urine. Clinical observations have given 
rise to the idea that FSGS can be associated with a causative circu-
lating factor, the so-called FSGS permeability factor, supported by 
the recurrence of FSGS after transplantation and by the response of 
proteinuria to therapy with plasmapheresis or immunoadsorption. 
Wei and colleagues report that serum soluble urokinase receptor 
(suPAR) is elevated in two-thirds of subjects with primary FSGS, 
but not in people with other glomerular diseases, particularly 
not in patients with minimal-change disease. They found that a 
higher concentration of suPAR before transplantation underlies 
an increased risk for recurrence of FSGS after transplantation 
(Figure). In three mouse models, the effects of suPAR on kidney 
function and morphology were explored and showed that circu-
lating suPAR activates podocyte b3-integrin in both native and 
grafted kidneys, causing foot process effacement, proteinuria, and 
FSGS-like glomerulopathy. These important findings suggest that 
the renal disease develops only when suPAR sufficiently activates 
podocyte b3-integrin. Thus, the disease can be abrogated by the 
lowering of serum suPAR concentrations through plasmapheresis, 
or by interfering with the suPAR–b3-integrin interaction through 
antibodies and small molecules targeting either podocyte uroki-
nase receptor (uPAR) or b3-integrin.
This study identifies serum suPAR as a circulating factor that 
may cause FSGS. Because suPAR is detectable both in healthy 
human subjects and in normal mice, physiological suPAR concen-
trations or physiological suPAR domain combinations do not seem 
to be harmful. Another interesting question is why a few patients 
without elevated suPAR still develop FSGS, as well as recurrent 
FSGS. An obvi ous answer would be that suPAR can act in concert 
with podocyte uPAR18, and this might drive FSGS even in the 
absence of high suPAR concentrations. This important original 
study opens pharmacological perspectives whereby modulation 
of excessive podocyte b3-integrin activation is a promising target 
for achieving protection from renal disease.
Marc De Broe
Differential impacts of blood 
pressure and lipid lowering on 
vascular disease of type 2 diabetes
Roman et al., Hypertension 2011; 58: 367–371; doi:10.1161/
HYPERTENSIONAHA.111.172486
Patients with diabetes have a high incidence of cardiovascular 
complications and kidney disease to which, in addition to hyper-
glycemia, both dyslipidemia and hypertension are likely to con-
tribute. The impact of blood pressure-lowering therapy on vascular 
abnormalities such as carotid artery thickness and left ventricular 
hypertrophy has been uniformly beneficial. In contrast, interven-
tion studies of lipid-lowering agents have generally demonstrated 
reductions in the progression, or actual regression, of vascular 
abnormalities, but outcomes have been variable. Roman et al. used 
the Stop Atherosclerosis in Native Diabetics Trial to examine the 
relative impacts of blood pressure lowering and lipid lowering on 
changes in arterial and left ventricular mass. The study was a ran-
domized trial of standard versus aggressive low-density lipoprotein 
(LDL) cholesterol and blood pressure targets in American Indians 
with type 2 diabetes mellitus. Subjects with type 2 diabetes mellitus 
and no preexisting clinical cardiovascular disease, LDL cholesterol 
greater than 100 mg/dl, and systolic blood pressure greater than 130 
mm Hg were enrolled at four clinical centers. Participants were ran-
domly assigned to aggressive lowering of LDL cholesterol (≤70 mg/
dl) and systolic blood pressure (≤115 mm Hg) versus standard care 
(LDL cholesterol ≤100 mg/dl and systolic blood pressure ≤130 mm 
Hg) and followed for 36 months. Interventions to lower and main-
tain LDL cholesterol and systolic blood pressure targets were based 
on National Cholesterol Education Program Adult Treatment Panel 
Table 1 | Baseline and 36-month values and their changes
Variable Baseline 36-Month Change P value
LDL cholesterol 
(mg/dl) 103 ± 28 87 ± 26 –16 ± 37 <0.001
Non-HDL 
cholesterol (mg/dl) 137 ± 31 119 ± 33 –18 ± 41 <0.001
Systolic BP  
(mm Hg) 130 ± 15 122 ± 12 –7 ± 15 <0.001
Arterial mass (mm2) 17.25 ± 4.60 17.72 ± 5.01 0.47 ± 2.71 <0.001
Arterial mass index 
(mm2/m2) 8.86 ± 2.41 9.10 ± 2.67 0.24 ± 1.51 0.001
LV mass (g) 157 ± 38 151 ± 38 –6 ± 23 <0.001
LV mass index  
(g/m2) 80 ± 17 77 ± 15 –2 ± 6 <0.001
Abbreviations: BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; LV, left ventricular.
suPAR measurement in the serum of subjects with glomerular 
disease. For transplant subjects, the suPAR values were measured from 
pretransplantation serum unless otherwise indicated. MCD, minimal-
change disease; MN, membranous nephropathy.
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III and Sixth Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure algorithms, 
respectively. The two treatment groups were combined to exam-
ine changes in left ventricular and arterial mass over a spectrum 
of achieved blood pressure and lipid levels. Among the combined 
group of 413 participants, systolic blood pressure, LDL cholesterol, 
and left ventricular mass were all significantly reduced, whereas 
arterial mass significantly increased, after 36 months of therapy 
(Table). In linear regression models, a decrease in arterial mass 
was significantly related to achieved systolic blood pressure and, 
to a lesser extent, achieved LDL cholesterol, after adjustment for 
important covariates. Left ventricular mass progressively decreased 
with lower achieved levels of systolic blood pressure, independently 
of baseline levels of left ventricular mass. Achieved levels of LDL 
cholesterol influenced regression of arterial but not ventricular 
mass. Thus, lowering systolic blood pressure is critical to reverse 
arterial and ventricular mass hypertrophy in diabetic individuals. 
The important point of the study is that it strongly suggests that in 
patients with diabetes there is no threshold of systolic blood pres-
sure below which regression of cardiovascular target organ damage 
cannot be achieved. This study together with the recent analysis1 
showing that blood pressure level rather than hyperglycemia was 
most important in determining cardiovascular damage in diabetes 
has highlighted the importance of very aggressive blood pressure–
lowering therapies for diabetic patients.
Juan Oliver
1Hypertension 2011; 57: 891–897.
Rituximab-induced depletion 
of anti-PLA2R autoantibodies 
predicts response in membranous 
nephropathy
Beck et al., J Am Soc Nephrol 2011; 22: 1543–1550; doi:10.1681/
ASN.2010111125
The recent identification of the M-type phospholipase A2 recep-
tor (PLA2R) as a major antigenic target in idiopathic membra-
nous nephropathy (IMN) is considered a major breakthrough 
for this disease. Autoantibodies reactive with this protein are a 
sensitive and specific marker for most cases of IMN. As there is 
no specific and highly effective therapy for IMN, the anti-B cell 
agent rituximab is considered as a promising therapy. Beck et al. 
investigated whether levels of anti-PLA2R correlate with clinical 
parameters such as proteinuria. They measured anti-PLA2R anti-
body titers in serial serum samples from a total of 35 patients with 
IMN treated with rituximab. Pretreatment samples from 25 of 35 
(71%) patients contained anti-PLA2R, and these autoantibodies 
declined or disappeared in 17 (68%) of these patients within 12 
months after rituximab. Of those with an immunologic response, 
59% and 88% attained complete or partial remission by 12 and 24 
months, respectively, compared with 0% and 33% among those 
with persistent anti-PLA2R levels. Changes in antibody levels pre-
ceded changes in proteinuria.
Thus, measuring anti-PLA2R levels may be a method to follow 
and predict response to treatment with rituximab in IMN with 
anti-PLA2R antibodies, and thereby help in guiding the immu-
nosuppressive therapy. It should be kept in mind, however, that 
the 25% of patients without anti-PLA2R antibodies had clinical 
responses to rituximab that were comparable to those of patients 
with antibodies, most likely indicating that other autoantibodies, 
yet to be identified, were responsible for the IMN.
Detlef Schlöndorff
Persistent asymptomatic isolated 
microscopic hematuria in Israeli 
adolescents and young adults and 
risk for end-stage renal disease
Vivante et al., JAMA 2011; 306; 729–736; doi:10.1001/jama.2011.1141
Few long-term studies on the natural history of previously defined 
benign conditions have been performed, because of the lack of 
available data sets. Vivante et al. examined the long-term outcome 
of otherwise healthy adolescents and young adults identified with 
microscopic hematuria without determined etiology. The study 
used the data set documenting this for a pre-military-service 
physical exam for recruits from 1975 to 1997 among people aged 
16–25 years, excluding those with known diseases that could 
result in damage to the kidney, such as diabetes, hypertension, 
and lupus. Persistent asymptomatic isolated microscopic hema-
turia was defined as five or more red blood cells per high-power 
field on three separate occasions. People with persistent asymp-
tomatic hematuria had to have a serum creatinine within normal 
range and no abnormality detected on renal imaging. The data set 
of people with and without persistent hematuria was then linked 
to the Israeli Treated End-Stage Renal Disease (ESRD) Registry, 
and individuals who had developed ESRD through 31 May 2010 
were identified. Approximately 1.24 million people underwent a 
medical exam, of whom 3690 had persistent microscopic hema-
turia. Of the approximately 1.20 million people who did not have 
hematuria by this definition, 539 developed ESRD by the end of 
the follow-up. Of the 3690 people with hematuria, 26 developed 
ESRD. There were few differences among people with and without 
hematuria. When those with persistent asymptomatic hematuria 
were compared with those without the condition who progressed 
to ESRD, people with hematuria were younger (34.7 versus 38.6 
years) and more likely to have an inflammatory glomerulopathy 
identified as the cause of their ESRD (for example, hereditary 
nephritis, IgA nephropathy). Finally, when the differences between 
people with and without hematuria were controlled for, persis-
tent asymptomatic microscopic hematuria was associated with a 
20-fold increased likelihood of progression to ESRD. 
This seminal study defines the natural history of a phenotype 
previously felt to be benign, suggesting that continued follow-up 
after initial evaluation is warranted to assess for progression of the 
kidney disease initially detected in its very early stages.
Lynda Szczech 
